InvestorRoom | Kitov Pharmaceuticals http://kitovpharma.investorroom.com/ Kitov to Host Business Update Conference Call on Monday, July 2 http://kitovpharma.investorroom.com/news-releases?item=66 Wed, 27 Jun 2018 03:23:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=66 Kitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy http://kitovpharma.investorroom.com/news-releases?item=65 Results in PDX model of pancreatic cancer supports planned IND for NT219 Fri, 15 Jun 2018 09:31:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=65 Kitov Announces Pricing of $8,150,000 Registered Direct Offering http://kitovpharma.investorroom.com/news-releases?item=63 Fri, 01 Jun 2018 08:40:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=63 FDA Approves Kitov’s Consensi™ for Treatment of Osteoarthritis Pain and Hypertension http://kitovpharma.investorroom.com/news-releases?item=64 New drug choice for millions of Americans offers one pill for treatment of osteoarthritis pain with a built-in antihypertensive Thu, 31 May 2018 13:45:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=64 Kitov Announces Consensi™ Commercialization Agreement for China http://kitovpharma.investorroom.com/news-releases?item=62 Kitov to receive milestone payments of up to $9.5 million, as well as potential double-digit royalties Fri, 11 May 2018 08:30:00 -0400 http://kitovpharma.investorroom.com/news-releases?item=62